Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Samuel S. Dychter"'
Autor:
Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Publikováno v:
Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)
ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/
Externí odkaz:
https://doaj.org/article/9727f714ed4549758640d27883f0f639
Autor:
Stephen J. Thomas, John L. Perez, Stephen P. Lockhart, Subramanian Hariharan, Nicholas Kitchin, Ruth Bailey, Katherine Liau, Eleni Lagkadinou, Özlem Türeci, Ugur Şahin, Xia Xu, Kenneth Koury, Samuel S. Dychter, Claire Lu, Teresa C. Gentile, William C. Gruber
Publikováno v:
Vaccine
Introduction Individuals with an underlying malignancy have high risk of poor COVID-19 outcomes. In clinical trials, COVID-19 vaccines were safe and efficacious against infection, hospitalization, and death, but most trials excluded participants with
Autor:
Kyung Hae Jung, Kan Yonemori, Anna V. Tinker, Rebecca Kristeleit, Ross A. Stewart, Fabian Zohren, Bradley J. Monk, Cristiana Sessa, Samuel S. Dychter, Gary Richardson, Radoslaw Madry, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Charles K. Anderson, Amit M. Oza, Keiichi Fujiwara, Caimiao Wei, Jonathan A. Ledermann, Susana Banerjee, Sang Yoon Park, Alexandra Leary
Publikováno v:
The Lancet Oncology. 22:1034-1046
Summary Background Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus peg
Autor:
Edson D, Moreira, Nicholas, Kitchin, Xia, Xu, Samuel S, Dychter, Stephen, Lockhart, Alejandra, Gurtman, John L, Perez, Cristiano, Zerbini, Michael E, Dever, Timothy W, Jennings, Donald M, Brandon, Kevin D, Cannon, Michael J, Koren, Douglas S, Denham, Mezgebe, Berhe, David, Fitz-Patrick, Laura L, Hammitt, Nicola P, Klein, Haylene, Nell, Georgina, Keep, Xingbin, Wang, Kenneth, Koury, Kena A, Swanson, David, Cooper, Claire, Lu, Özlem, Türeci, Eleni, Lagkadinou, Dina B, Tresnan, Philip R, Dormitzer, Uğur, Şahin, William C, Gruber, Kathrin U, Jansen
Publikováno v:
The New England journal of medicine. 386(20)
Active immunization with the BNT162b2 vaccine (Pfizer-BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of re
Autor:
Samuel S. Dychter, Daniel C. Beachler, Patrice Verpillat, Ruihua Yin, Leo Russo, Francois-Xavier Lamy, Stephan Lanes, Devon H. Taylor, Jade Dinh, Aziza Jamal-Allial
Publikováno v:
Journal of Ovarian Research, Vol 13, Iss 1, Pp 1-13 (2020)
Journal of Ovarian Research
Journal of Ovarian Research
Background Detailed epidemiologic descriptions of large populations of advanced stage ovarian cancer patients have been lacking to date. This study aimed to describe the patient characteristics, treatment patterns, survival, and incidence rates of he
Autor:
Daniel C. Maneval, David W. Kang, Marie A. Printz, Samuel S. Dychter, Barry J. Sugarman, Rena Harrigan, Monica L. Zepeda, Jennifer Souratha, Emanuel P. DeNoia
Publikováno v:
Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Vol 93, Iss, Pp 100604-(2020)
Current Therapeutic Research, Vol 93, Iss, Pp 100604-(2020)
Background Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronida
Autor:
Susana Banerjee, Kan Yonemori, Gary Richardson, Bradley J. Monk, Kyung Hae Jung, Jonathan A. Ledermann, Amit M. Oza, Caimiao Wei, Charles K. Anderson, Cristiana Sessa, Alexandra Leary, Eric Pujade-Lauraine, Anna V. Tinker, Ross A. Stewart, Fabian Zohren, Keiichi Fujiwara, Rebecca Kristeleit, Radoslaw Madry, Sang Yoon Park, Samuel S. Dychter, I.L. Ray-Coquard
Publikováno v:
SSRN Electronic Journal.
Background: This phase 3 trial (JAVELIN Ovarian 200) compared avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. Methods: Eligible women (≤
Publikováno v:
Future Oncology. 14:2103-2113
Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase III trial to evaluate the role of checkp
Autor:
Anna V. Tinker, Kan Yonemori, Sang Yoon Park, Caimiao Wei, I.L. Ray-Coquard, Bradley J. Monk, Susana Banerjee, Charles K. Anderson, Jonathan A. Ledermann, Ross A. Stewart, Fabian Zohren, Eric Pujade-Lauraine, Kyung Hae Jung, Rebecca Kristeleit, Radoslaw Madry, Samuel S. Dychter, Alexandra Leary, Amit M. Oza, Gary Richardson, Cristiana Sessa, Keiichi Fujiwara
Publikováno v:
Gynecologic Oncology. 154:21-22
Autor:
Rena Harrigan, Daniel Fellows, Emanuel P. DeNoia, Samuel S. Dychter, Daniel C. Maneval, Jesse Bahn, Barry J. Sugarman, Marie A. Printz, David B. Haughey
Publikováno v:
Clinical Therapeutics. 36:211-224
Background Subcutaneous ondansetron facilitated by recombinant human hyaluronidase PH20 (rHuPH20) is an alternative for treating nausea/vomiting in patients who cannot receive ondansetron by other routes of administration. Objective Based on preclini